MX364040B - Uso farmacéutico de una composición que contiene pirfenidona de liberación prolongada (pfd-lp) para la reversión y tratamiento de la esteatohepatitis humana (nafld/nash). - Google Patents

Uso farmacéutico de una composición que contiene pirfenidona de liberación prolongada (pfd-lp) para la reversión y tratamiento de la esteatohepatitis humana (nafld/nash).

Info

Publication number
MX364040B
MX364040B MX2016014775A MX2016014775A MX364040B MX 364040 B MX364040 B MX 364040B MX 2016014775 A MX2016014775 A MX 2016014775A MX 2016014775 A MX2016014775 A MX 2016014775A MX 364040 B MX364040 B MX 364040B
Authority
MX
Mexico
Prior art keywords
nafld
nash
treatment
pirfenidone
esteatohepatitis
Prior art date
Application number
MX2016014775A
Other languages
English (en)
Spanish (es)
Other versions
MX2016014775A (es
Inventor
Agustín Rogelio Magaña Castro José
Socorro Armendáriz Borunda Juan
HERNÁNDEZ ALDANA Nadiel
Original Assignee
Cell Therapy And Tech S A De C V
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cell Therapy And Tech S A De C V filed Critical Cell Therapy And Tech S A De C V
Priority to MX2016014775A priority Critical patent/MX364040B/es
Priority to JOP/2019/0102A priority patent/JOP20190102A1/ar
Priority to AU2017358367A priority patent/AU2017358367B2/en
Priority to EP17840578.3A priority patent/EP3539537A1/en
Priority to KR1020197014274A priority patent/KR20190084056A/ko
Priority to UY0001037478A priority patent/UY37478A/es
Priority to CN201780076430.3A priority patent/CN110248646A/zh
Priority to KR1020247015017A priority patent/KR20240065330A/ko
Priority to PE2019000946A priority patent/PE20191149A1/es
Priority to MA45754A priority patent/MA45754A1/fr
Priority to US16/348,189 priority patent/US20190262325A1/en
Priority to CA3043300A priority patent/CA3043300A1/en
Priority to RU2019116422A priority patent/RU2019116422A/ru
Priority to CN202211265065.XA priority patent/CN115969802A/zh
Priority to JP2019547064A priority patent/JP2019535822A/ja
Priority to PCT/MX2017/000129 priority patent/WO2018088886A1/es
Priority to ARP170103142A priority patent/AR110057A1/es
Publication of MX2016014775A publication Critical patent/MX2016014775A/es
Publication of MX364040B publication Critical patent/MX364040B/es
Priority to ECSENADI201931851A priority patent/ECSP19031851A/es
Priority to IL266519A priority patent/IL266519A/en
Priority to CL2019001280A priority patent/CL2019001280A1/es
Priority to PH12019501047A priority patent/PH12019501047A1/en
Priority to CONC2019/0004799A priority patent/CO2019004799A2/es
Priority to ZA2019/03012A priority patent/ZA201903012B/en
Priority to JP2022152261A priority patent/JP2022173344A/ja
Priority to US18/051,937 priority patent/US20230181550A1/en
Priority to AU2024200737A priority patent/AU2024200737A1/en
Priority to US18/965,593 priority patent/US20250325530A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
MX2016014775A 2016-11-11 2016-11-11 Uso farmacéutico de una composición que contiene pirfenidona de liberación prolongada (pfd-lp) para la reversión y tratamiento de la esteatohepatitis humana (nafld/nash). MX364040B (es)

Priority Applications (27)

Application Number Priority Date Filing Date Title
MX2016014775A MX364040B (es) 2016-11-11 2016-11-11 Uso farmacéutico de una composición que contiene pirfenidona de liberación prolongada (pfd-lp) para la reversión y tratamiento de la esteatohepatitis humana (nafld/nash).
JOP/2019/0102A JOP20190102A1 (ar) 2016-11-11 2017-06-16 استخدام صيدلي لتركيب له إطلاق ممتد يحتوي على بيرفنيدون من أجل علاج والتعافي من التهاب الكبد الدهني البشري ((داء الكبد الدهني غير الكحولي nafld)/التهاب الكبد الدهني غير الكحولي nash))
CN202211265065.XA CN115969802A (zh) 2016-11-11 2017-11-09 含吡非尼酮缓释组合物用于治疗和逆转人脂肪性肝炎的药物用途
PCT/MX2017/000129 WO2018088886A1 (es) 2016-11-11 2017-11-09 Uso farmacéutico de una composición que contiene pirfenidona de liberación prolongada (pfd-lp) para la reversión y tratamiento de la esteatohepatitis humana (nafld/nash)
KR1020197014274A KR20190084056A (ko) 2016-11-11 2017-11-09 인간 지방간염(nafld/nash)의 치료 및 역행을 위한 서방성 피르페니돈 함유 조성물의 약학적 용도
UY0001037478A UY37478A (es) 2016-11-11 2017-11-09 Uso farmacéutico de una composición que contiene pirfenidona de liberación prolongada (pfd-lp) para la reversión y tratamiento de la esteatohepatitis humana (nafld/nash)
CN201780076430.3A CN110248646A (zh) 2016-11-11 2017-11-09 包含吡非尼酮的缓释组合物用于治疗和逆转人脂肪性肝炎(nafld/nash)的药物用途
KR1020247015017A KR20240065330A (ko) 2016-11-11 2017-11-09 인간 지방간염(nafld/nash)의 치료 및 역행을 위한 서방성 피르페니돈 함유 조성물의 약학적 용도
PE2019000946A PE20191149A1 (es) 2016-11-11 2017-11-09 Uso farmaceutico de una composicion que contiene pirfenidona de liberacion prolongada (pfd-lp) para la reversion y tratamiento de la esteatohepatitis humana (nafld/nash)
MA45754A MA45754A1 (fr) 2016-11-11 2017-11-09 Utilisation pharmaceutique d'une composition à base de pirfénidone à libération prolongée (pfd-lp) pour la réversion de la stéatose hépatique humaine (nafld/nash)
US16/348,189 US20190262325A1 (en) 2016-11-11 2017-11-09 Pharmaceutical use of an extended-release composition containing pirfenidone for the treatment and reversal of human steatohepatitis (nafld/nash)
CA3043300A CA3043300A1 (en) 2016-11-11 2017-11-09 Pharmaceutical use of an extended-release composition containing pirfenidone for the treatment and reversal of human steatohepatitis (nafld/nash)
RU2019116422A RU2019116422A (ru) 2016-11-11 2017-11-09 Фармацевтическое применение композиции пролонгированного действия, содержащей пирфенидон, для лечения и обращения течения стеатогепатита человека (nafld/nash)
AU2017358367A AU2017358367B2 (en) 2016-11-11 2017-11-09 Pharmaceutical use of an extended-release composition containing pirfenidone for the treatment and reversal of human steatohepatitis (NAFLD/NASH)
JP2019547064A JP2019535822A (ja) 2016-11-11 2017-11-09 ヒト脂肪性肝炎（ｎａｆｌｄ／ｎａｓｈ）の治療及び回復に対するピルフェニドンを含む持続放出性の組成物の薬学的使用
EP17840578.3A EP3539537A1 (en) 2016-11-11 2017-11-09 Pharmaceutical use of an extended-release composition containing pirfenidone for the treatment and reversal of human steatohepatitis (nafld/nash)
ARP170103142A AR110057A1 (es) 2016-11-11 2017-11-10 Uso farmacéutico de una composición que contiene pirfenidona de liberación prolongada (pfd-lp) para la reversión y tratamiento de la esteatohepatitis humana (nafld / nash)
ECSENADI201931851A ECSP19031851A (es) 2016-11-11 2019-05-08 Uso farmacéutico de una composición que contiene pirfenidona de liberación prolongada (pfd-lp) para la reversión y tratamiento de la esteatohepatitis humana (nafld/nash)
IL266519A IL266519A (en) 2016-11-11 2019-05-08 Pharmaceutical use of a sustained-release preparation containing pirfenidone for the treatment and reversal of human steatohepatitis (NAFLD/NASH)
CL2019001280A CL2019001280A1 (es) 2016-11-11 2019-05-09 Uso farmacéutico de una composición que contiene pirfenidona de liberación prolongada (pfd-lp) para la reversión y tratamiento de la esteatohepatitis humana (nafld/nash).
PH12019501047A PH12019501047A1 (en) 2016-11-11 2019-05-10 Pharmaceutical use of an extended-release composition containing pirfenidone for the treatment and reversal of human steatohepatitis (nafld/nash)
CONC2019/0004799A CO2019004799A2 (es) 2016-11-11 2019-05-10 Uso farmacéutico de una composición que contiene pirfenidona de liberación prolongada (pfd-lp) para la reversión y tratamiento de la esteatohepatitis humana (nafld/nash)
ZA2019/03012A ZA201903012B (en) 2016-11-11 2019-05-14 Pharmaceutical use of an extended-release composition containing pirfenidone for the treatment and reversal of human steatohepatitis (nafld/nash)
JP2022152261A JP2022173344A (ja) 2016-11-11 2022-09-26 ヒト脂肪性肝炎（ｎａｆｌｄ／ｎａｓｈ）の治療及び回復に対するピルフェニドンを含む持続放出性の組成物の薬学的使用
US18/051,937 US20230181550A1 (en) 2016-11-11 2022-11-02 Pharmaceutical use of an extended-release composition containing pirfenidone for the treatment and reversal of human steatohepatitis (nafld/nash)
AU2024200737A AU2024200737A1 (en) 2016-11-11 2024-02-07 Pharmaceutical use of an extended-release composition containing pirfenidone for the treatment and reversal of human steatohepatitis (nafld/nash)
US18/965,593 US20250325530A1 (en) 2016-11-11 2024-12-02 Pharmaceutical use of an extended-release composition containing pirfenidone for the treatment and reversal of human steatohepatitis (nafld/nash)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
MX2016014775A MX364040B (es) 2016-11-11 2016-11-11 Uso farmacéutico de una composición que contiene pirfenidona de liberación prolongada (pfd-lp) para la reversión y tratamiento de la esteatohepatitis humana (nafld/nash).

Publications (2)

Publication Number Publication Date
MX2016014775A MX2016014775A (es) 2018-05-10
MX364040B true MX364040B (es) 2019-04-11

Family

ID=61193005

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2016014775A MX364040B (es) 2016-11-11 2016-11-11 Uso farmacéutico de una composición que contiene pirfenidona de liberación prolongada (pfd-lp) para la reversión y tratamiento de la esteatohepatitis humana (nafld/nash).

Country Status (21)

Country Link
US (3) US20190262325A1 (enExample)
EP (1) EP3539537A1 (enExample)
JP (2) JP2019535822A (enExample)
KR (2) KR20190084056A (enExample)
CN (2) CN110248646A (enExample)
AR (1) AR110057A1 (enExample)
AU (2) AU2017358367B2 (enExample)
CA (1) CA3043300A1 (enExample)
CL (1) CL2019001280A1 (enExample)
CO (1) CO2019004799A2 (enExample)
EC (1) ECSP19031851A (enExample)
IL (1) IL266519A (enExample)
JO (1) JOP20190102A1 (enExample)
MA (1) MA45754A1 (enExample)
MX (1) MX364040B (enExample)
PE (1) PE20191149A1 (enExample)
PH (1) PH12019501047A1 (enExample)
RU (1) RU2019116422A (enExample)
UY (1) UY37478A (enExample)
WO (1) WO2018088886A1 (enExample)
ZA (1) ZA201903012B (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2007009796A (es) 2007-08-14 2009-02-25 Cell Therapy And Technology S Gel conteniendo pirfenidona.
MX2011007675A (es) 2011-07-19 2012-07-11 Cell Therapy And Technology S A De C V Procedimiento para la fabricacion de una composicion farmaceutica en forma de tabletas de liberacion prolongada conteniendo pirfenidona y su aplicacion en la regresion de la insuficiencia renal cronica, contractura capsular mamaria y fibrosis hepatica humanas.
MX346763B (es) 2012-03-28 2017-03-31 Cell Therapy And Tech S A De C V Composición tópica semisólida conteniendo pirfenidona y dialil óxido de disulfuro modificado (odd-m) para eliminar o prevenir el acné.
MX356551B (es) 2012-08-23 2018-06-04 Grupo Medifarma S A De C V Star Composición antiséptica, antiseborreica y exfoliante para eliminar o prevenir el acné.
MX366086B (es) 2017-08-15 2019-06-27 Cell Therapy And Tech S A De C V Composicion topica semisolida conteniendo un agente antimicrobiano y pirfenidona para el tratamiento de daños cronicos de la piel.
EP3716975A4 (en) * 2017-11-28 2022-01-12 Eiger Biopharmaceuticals, Inc. METHODS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF NON-ALCOHOLIC STEATOHEPATITIS
WO2020115774A1 (en) 2018-12-06 2020-06-11 Cipla Limited High drug load extended release formulations
EP4232063A4 (en) * 2020-10-23 2025-01-01 HAN, Hq BIFUNCTIONAL ANTAGONISTS OF TUMOR NECROSIS FACTOR-ALPHA AND TRANSFORMING GROWTH FACTOR-BETA AND THEIR USES
CN117007806A (zh) * 2023-09-21 2023-11-07 中国人民解放军军事科学院军事医学研究院 靶向肝巨噬细胞内lxr用于控制慢乙肝进展

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60234812D1 (de) * 2001-01-29 2010-02-04 Shionogi & Co Arzneipräparat, das als wirkstoff 5-methyl-1-phenyl-2-(1h)-pyridon enthält
US20080025986A1 (en) * 2003-06-06 2008-01-31 Ozes Osman N Methods of Treating Tnf-Mediated Disorders
CN100542532C (zh) * 2004-05-24 2009-09-23 上海睿星基因技术有限公司 吡非尼酮在制备治疗肝损伤坏死和急性肺损伤的药物中的用途
WO2010048716A1 (en) * 2008-10-29 2010-05-06 Pacific Therapeutics Ltd. Composition and method for treating fibrosis
US7635707B1 (en) * 2008-11-10 2009-12-22 Intermune, Inc. Pirfenidone treatment for patients with atypical liver function
CN101972236A (zh) * 2010-10-13 2011-02-16 北京诚创康韵医药科技有限公司 一种含吡非尼酮的缓释制剂
MX2011007675A (es) * 2011-07-19 2012-07-11 Cell Therapy And Technology S A De C V Procedimiento para la fabricacion de una composicion farmaceutica en forma de tabletas de liberacion prolongada conteniendo pirfenidona y su aplicacion en la regresion de la insuficiencia renal cronica, contractura capsular mamaria y fibrosis hepatica humanas.
CN102488660A (zh) * 2011-12-15 2012-06-13 西安天一秦昆制药有限责任公司 一种含吡非尼酮的缓释微丸
CN103550242B (zh) * 2013-11-22 2015-07-15 四川国康药业有限公司 一种治疗肝纤维化的药物组合物及其制备方法

Also Published As

Publication number Publication date
AR110057A1 (es) 2019-02-20
CL2019001280A1 (es) 2019-07-19
KR20190084056A (ko) 2019-07-15
IL266519A (en) 2019-07-31
AU2024200737A1 (en) 2024-02-22
JP2019535822A (ja) 2019-12-12
EP3539537A1 (en) 2019-09-18
AU2017358367A1 (en) 2019-05-30
PH12019501047A1 (en) 2019-12-11
ZA201903012B (en) 2020-09-30
RU2019116422A (ru) 2020-12-11
AU2017358367B2 (en) 2023-11-09
US20250325530A1 (en) 2025-10-23
JP2022173344A (ja) 2022-11-18
CA3043300A1 (en) 2018-05-17
CN110248646A (zh) 2019-09-17
US20230181550A1 (en) 2023-06-15
ECSP19031851A (es) 2019-06-30
MA45754A1 (fr) 2019-12-31
US20190262325A1 (en) 2019-08-29
PE20191149A1 (es) 2019-09-02
JOP20190102A1 (ar) 2019-05-06
RU2019116422A3 (enExample) 2021-04-09
CN115969802A (zh) 2023-04-18
WO2018088886A1 (es) 2018-05-17
CO2019004799A2 (es) 2019-07-31
KR20240065330A (ko) 2024-05-14
UY37478A (es) 2018-05-31
MX2016014775A (es) 2018-05-10

Similar Documents

Publication Publication Date Title
CO2019004799A2 (es) Uso farmacéutico de una composición que contiene pirfenidona de liberación prolongada (pfd-lp) para la reversión y tratamiento de la esteatohepatitis humana (nafld/nash)
CR20170129A (es) Uso de un agonista dual del receptor de glp-1/glucagón de acción prolongada para el tratamiento de la enfermedad del hígado graso no alcohólico
CL2016001609A1 (es) Composiciones farmacéuticas que comprenden azd9291.
MX2018006578A (es) Formulaciones farmaceuticas topicas para tratar afecciones inflamatorias.
CL2015003395A1 (es) Derivados pirazolopirrolidina y su uso en el tratamiento de la enfermedad
Adler et al. Glucocorticoid-induced osteoporosis
HRP20190573T1 (hr) Piranokromenil fenol derivat, i farmaceutska kompozicija za liječenje metaboličkog sindroma ili inflamatorne bolesti
BR112016021034A2 (pt) Composição farmacêutica, uso de tal composição, método para tratar uma doença e kit
IL272457A (en) GLP-1/Glucagon agonist receptors in the treatment of fatty liver disease and steatohepatitis
BR112012020989A2 (pt) composições veterinárias
EP3363450A4 (en) TRADITIONAL CHINESE MEDICAL COMPOSITION FOR THE TREATMENT OF PSORIASIS
CL2017001615A1 (es) Pirazolpiridinaminas como inhibidores de mknk1 y mknk2.
ITUA20162575A1 (it) Composizione farmaceutica o nutraceutica per l’uso nel trattamento della sindrome dell’ovaio policistico o di malattie o disturbi correlati ad essa
CL2015001936A1 (es) Composición y su uso que sirve para preparar un medicamento útil para tratar enfermedades relacionadas con el factor inducible por hipoxia (hif).
NZ739867A (en) Aminonaphthoquinone compounds and pharmaceutical composition for blocking ubiquitination-proteasome system in diseases
BR112017017729A2 (pt) forma de dosagem oral de liberação controlada de agonista de receptor gaba
MX390011B (es) Metodos y composiciones para inhibir los sintomas asociados con la veisalgia.
CO2017007874A2 (es) Composiciones y métodos para metabolismo muscular mejorado
PT3094616T (pt) O uso de uma composição que contém tribenzoato de glicerilo em distúrbios neurodegenerativos
EP3316874A4 (en) TOPICAL AND INJECTABLE RESIQUIMOD COMPOSITIONS FOR THE TREATMENT OF NEOPLASTIC GUM DISEASES
EA201690191A1 (ru) Фармацевтическая композиция для замедленного высвобождения ланреотида
MX2016011025A (es) Composiciones de grapiprant y metodos para usar las mismas.
IL285776A (en) Useful preparations in the treatment of Kraba's disease
MX2017011904A (es) Composiciones para el tratamiento de fibrosis y afecciones relacionadas con fibrosis.
CL2015003211A1 (es) Combinación sinergística de paracetamol/celecoxib para el tratamiento de dolor inflamatorio.

Legal Events

Date Code Title Description
FG Grant or registration